As of 2025-07-04, the Intrinsic Value of Relmada Therapeutics Inc (RLMD) is -11.41 USD. This RLMD valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.63 USD, the upside of Relmada Therapeutics Inc is -1,910.42%.
Based on its market price of 0.63 USD and our intrinsic valuation, Relmada Therapeutics Inc (RLMD) is overvalued by 1,910.42%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -11.41 - -11.41 | -11.41 | -1,910.42% |
| P/E | (43.84) - (42.11) | (44.03) | -7088.2% |
| DDM - Stable | (16.90) - (47.02) | (31.96) | -5173.0% |
| DDM - Multi | (15.50) - (34.31) | (21.44) | -3503.6% |
| Market Cap (mil) | 20.91 |
| Beta | 2.36 |
| Outstanding shares (mil) | 33.19 |
| Enterprise Value (mil) | 19.76 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.91% |
| Cost of Debt | 5.00% |
| WACC | 7.29% |